01 — At a Glance
The Enzyme That’s Slowly Digesting Investor Hopes
- 52-Week High / Low₹367 / ₹259
- Q3 FY26 Revenue₹172 Cr
- Q3 PAT₹43.2 Cr
- Q3 EPS₹3.80
- Annualised EPS (Q3×4)₹15.20
- Book Value₹133
- Price to Book2.05x
- Dividend Yield1.92%
- Debt / Equity0.02x
- 9M FY26 Revenue₹543 Cr
CEO’s Honest Confession (Buried in Footnote): Q3 was operationally soft. The margin chart looks like a ski slope. U.S. nutraceutical demand is “uncertain.” But hey, 9M revenue is up 15% YoY, so technically we’re still winning. Just not in quarters three. Or maybe four. We’ll get back to you on that.
02 — Introduction
India’s Enzyme King Is Having an Identity Crisis
Advanced Enzyme Technologies. The name alone screams “I make things that make things work.” Which they do. They make enzymes. Enzymes are proteins that catalyze chemical reactions. They help pharma companies, nutraceutical companies, animal feed manufacturers, textile mills, and breweries do their jobs. Think of enzymes as the microscopic workers inside your supplement bottle. Invisible, essential, and deeply unglamorous.
The company is the 1st Indian enzyme manufacturer and 2nd integrated enzyme company globally. They export to 45+ countries. They have 700+ customers. They own 9 manufacturing plants and operate 7 R&D centres. On paper, this is a fortress. On the stock price chart, it’s a ski slope.
Here’s the thing: Enzyme companies are specialist manufacturers in a niche market. They’re not sexy. You won’t see them on Shark Tank. Your mom won’t ask you at dinner, “Beta, did you invest in enzymes?” But they’re profitable, they generate cash, and they’re growing. Just… slowly. And with more turbulence than a turbocharged flight to Goa.
FY25 revenue was ₹637 crore. FY26 target? Nobody knows. But Q3 happened, margins got destroyed, and now management is talking about a “roller coaster” ride through 2026. Buckle up.
Concall Gold Nugget (Feb 2026): Management said growth “13% to 15%… continuous basis” over 3–5 years, but also said “the ride will be roller coaster.” This is the corporate equivalent of “I promise to call you back” — technically not a lie, just deeply optimistic.
03 — Business Model: Making Stuff That Makes Stuff Work
They Ferment. You Consume. Universe Continues.
Advanced Enzyme makes enzymes via fermentation. They buy substrate and culture media, grow specialized microorganisms (mostly bacteria and fungi), extract the enzyme, purify it, formulate it into products, and sell it globally. Four hundred-plus proprietary products. Sixty-eight different enzyme types. Seven different application segments.
Human Healthcare (56% of Q3 revenue): Enzymes for pharma and nutraceutical companies. Anti-inflammatory enzymes, digestive enzymes, enzymes for liver health. Their biggest product — Serratiopeptidase (an anti-inflammatory enzyme) — accounts for 21% of quarterly revenue. One enzyme. 21% of revenue. If that product gets disrupted or lost to a competitor, the stock probably crashes 30%.
Animal Nutrition (14% of Q3): Enzymes that help birds and pigs digest feed better. Currently growing 22% YoY. This is the rockstar segment. Everyone’s buying it. Meanwhile, the Human Healthcare segment is declining 6% YoY. The irony is delicious.
Industrial Bioprocessing (16% of Q3): Enzymes for textiles, leather, detergent, pulp & paper, and food manufacturing. Growing. But slow. Non-food bioprocessing is flat. Food bioprocessing is robust at +19% 9M growth.
Specialized Manufacturing (9% of Q3): Effervescent tablets and sachets. Dormant for years. Now management is breathing life into it. “We’re evaluating textile and disinfectant segments,” they say. Translation: We’re still testing products that nobody is ordering yet.
Geography: 50% India. 33% Americas (aka “U.S. nervousness”). 6% Europe. The concentration in North America is the single biggest risk.
Human Healthcare56%Q3 Revenue Mix
Animal Nutrition14%Q3 Revenue Mix
Bioprocessing16%Q3 Revenue Mix
Specialized Mfg9%Q3 Revenue Mix
Working capital? A nightmare. Inventory is 378 days. They need to buy raw materials 100+ days before they’re paid by customers. This is why cash flow feels like a constipated audit — painfully slow, occasionally surprising, always uncomfortable.
💬 Have you ever invested in a “boring” sector like enzymes and just expected it to compound quietly? Drop your nightmare story in the comments!
04 — Financials Overview
Q3 FY26: The Soft Landing That Wasn’t
Result type: Quarterly Results | Q3 FY26 EPS: ₹3.80 | Annualised EPS (Q3×4): ₹15.20 | FY25 Full Year EPS: ₹11.72
| Metric (₹ Mn) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 17,195 | 16,914 | 18,485 | +1.7% | -7.0% |
| EBITDA | 4,943 | 5,544 | 6,043 | -10.8% | -18.2% |
| EBITDA Margin % | 29% | 33% | 33% | -400 bps | -400 bps |
| PAT | 4,318 | 3,889 | 4,496 | +11.0% | -4.0% |
| EPS (₹) | 3.80 | 3.37 | 3.87 | +12.8% | -1.8% |
⚠️ The Margin Collapse is Real: Q3 EBITDA margin dropped from 33% to 29% — a 400-basis-point cliff. Revenue barely grew (+1.7% YoY), but margins contracted sharply. Management attributed this to “mix, volume, and cost actions.” Translation: U.S. tariffs hit harder than expected, input costs spiked, customer hesitation kicked in, and pricing power evaporated. Meanwhile, PAT actually grew 11% YoY because of below-EBITDA line benefits (depreciation, other income, tax). This is the financial equivalent of a magic trick — the profit grew while the business shrunk.
05 — Valuation Discussion: Fair Value Range Only
What’s This Company Actually Worth?
